Acrivon Therapeutics, Inc. Common Stock
NASDAQ:ACRVBiotechnology
Healthcare
$1.40 +3.16%
+$0.05 today
- Market cap
- $60.08M
- Beta
- 1.91
- P/E (TTM)
- -0.8
- EPS (TTM)
- -$2.00
52W Low $1.15High $3.56
Volume 0.37M
Average 0.60M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$63.66M
FY 2025 · Annual
Investing Cash Flow
$66.10M
FY 2025 · Annual
Financing Cash Flow
-$749,000.00
FY 2025 · Annual
Cash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (16.24M) | (31.17M) | (60.39M) | (80.56M) | (77.91M) |
| Depreciation & Amortization | 37K | 364K | 536K | 1.01M | 919K |
| Deferred Income Tax | 0 | 0 | (3.61M) | 0 | 0 |
| Stock-Based Compensation | 497K | 2.19M | 11.62M | 14.29M | 14.72M |
| Change in Working Capital | 328K | (1.53M) | 8.14M | 2.44M | (2.43M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 798K | (245K) | 3.61M | (3.59M) | 1.54M |
| Other Working Capital | (470K) | (1.29M) | 4.53M | 6.02M | (3.96M) |
| Other Non-Cash Items | 1.4M | 33K | 1.06M | (2.85M) | 1.03M |
| Operating Cash Flow | (13.98M) | (30.12M) | (42.64M) | (65.67M) | (63.67M) |
| Capital Expenditures | (238K) | (2.17M) | (1.29M) | (2.77M) | (1.67M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (150.18M) | (56.53M) | (202.93M) | (81.73M) |
| Sales of Investments | 0 | 10.67M | 108.53M | 153.92M | 149.5M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (238K) | (141.68M) | 50.72M | (51.77M) | 66.1M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 104.46M | (257K) | 70M | 1K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1K | (2.75M) | (1.3M) | 51.03M | (750K) |
| Financing Cash Flow | 112.22M | 101.71M | (1.55M) | 121.03M | (749K) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 98M | (70.08M) | 6.52M | 3.59M | 1.69M |
| Free Cash Flow | (14.22M) | (32.28M) | (43.93M) | (68.44M) | (65.33M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$77.9M
+ D&A$919.0K
+ Stock-Based Comp$14.7M
+ Deferred Tax$0
- Working Capital-$2.4M
+ Other Non-Cash$1.0M
= Operating Cash Flow-$63.7M
- Capex-$1.7M
= Free Cash Flow-$65.3M
Analysis
FY2025 free cash flow is -$65.3M. FCF conversion is 83.9% of net income. Operating cash flow was -$63.7M, with capex of -$1.7M. The largest bridge item is Stock-Based Comp at $14.7M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 10, 2026 | |
| 8-K | Current report | Nov 6, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 26, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 7, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 2, 2026 |
Does ACRV generate free cash flow?
Acrivon Therapeutics, Inc. Common Stock (ACRV) generated -$65.33M of free cash flow in fiscal 2025.
How much operating cash flow does ACRV produce?
Operating cash flow was -$63.66M, before capital expenditures of $1.67M.
Continue the stock analysis
Jump to another research area for this company.